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OBJECTIVE: The objective of this study was to assess
consistency between qualitative (NCEP-II) and quantita-
tive methods used to recommend cholesterol reduction 
in individuals without coronary heart disease in Spain.
METHODS: Qualitative (NCEP-II) and quantitative 
recommendations for cholesterol reduction were applied
to individuals without coronary heart disease (n = 304)
studied in a random sample of the adult population 
of Catalonia aged > years. Pharmaceutical treatment 
of hypercholesterolemia should be recommended for 
individuals with a LDL cholesterol concentration 
>190mg/dl or 160–189mg/dl with at least two other 
risk factors based on the NCEP-II method, and 
to individuals with a coronary heart disease risk in 10
years >20% based on the quantitative method. Dietary
treatment should be recommended for those detected
with the NCEP-II method and for those with a coronary
heart disease risk in 10 years >10%. Concordance
between both the qualitative and quantitative method
was assessed using the Kappa index. RESULTS: Pharma-
ceutical treatment of hypercholesterolemia should be rec-
ommended in 20,0% of men and 20,1% of women based
on the NCEP-II method and to 24% of men and 33,1%
based on the quantitative method. Concordance was low
(Kappa = 0,31) in men and moderate (Kappa = 0,45) in
women between the qualitative and quantitative method.
Hypercholesterolemia >240mg/dl was the main factor
explaining recommendations based on the NCEP-II
method (ORadj = 64), while age, hypertension and hyper-
cholesterolemia explained recommendations based on the
quantitative method. CONCLUSION: Results obtained
in this study showed a low concordance between quali-
tative and quantitative methods to recommend choles-
terol reduction in individuals without coronary heart
disease.
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OBJECTIVES: Three current guidelines for the manage-
ment of hypertension (JNC-VI 1997, WHO/ISH 1999,
BHS 1999) were compared with respect to their potential
impacts on rates of treatment indication. METHODS:
After systematic comparisons, the divergent recommen-
dations of the three guidelines were operationalized. 
Speciﬁc complex algorithms were developed for each
guideline to calculate the percentage of the population
with an indication for antihypertensive treatment (=
indication rates). Each guideline-speciﬁc algorithm was
applied to 10.460 men and women aged 35–74 from a
representative sample of the WHO-MONICA-Augsburg
study population. The computation was performed in
groups according to the risk strata of the three guidelines.
Additionally age-, gender- and blood-speciﬁc indication
rates were calculated. RESULTS: Each guideline uses
complex but different structures for the determination of
treatment indications. Generally, men had a higher treat-
ment rate than women independent of guideline applied.
Within each age decade, the guideline speciﬁc indication
rates differed by about ﬁve percent points. The age-
speciﬁc differences decreased with higher age within JNC,
were stable within WHO and increased within the BHS-
guideline. There were signiﬁcant differences of indication
rate by blood pressure categories below 160/90mmHg.
CONCLUSION: Different stringent conditions of anti-
hypertensive treatment indications are based on differing
inﬂuences of blood pressure, age and gender as potential
risk factors. The different risk stratiﬁcations may lead to
highly divergent economic consequences.
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OBJECTIVE: As part of an “outcomes program” on
smoking cessation, we thought it relevant to evaluate in
smokers under 25 years of age the obstacles to cessation,
the level of dependency, the knowledge of tobacco depen-
dency and the propensity to pay for cessation treatment.
METHOD: For this pilot phase, an anonymous ques-
tionnaire was distributed in the “Student” supplement 
of a French regional weekly newspaper (Tarn Libre).
RESULTS: Obstacles to cessation: lack of willpower
(51%), enjoyment of smoking (32%), force of habit
(46%). The level of dependency on tobacco was evalu-
ated using the Fagerström test: 48% had low dependency,
48% moderate dependency and 2% high dependency. 
In general, our sample population had a good general
knowledge and understanding of tobacco use (number 
of premature deaths per year, percentage of smokers in
France, cost of tobacco for health insurance). Average
daily tobacco expenses were €2.3 (roughly corresponding
to an average consumption of 10 cigarettes/day), and the
subjects declared themselves ready to pay around €83 to
stop smoking (€157 in older adults). This ﬁgure is rela-
tively low and is explained without doubt by an under-
estimation of the potential risks of tobacco dependency.
